Najibah Nasrin

Najibah Nasrin

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Scientifica
Verified
Journal Article
Open access
NSNawfal Hasan Siam
Nawfal Hasan Siam
NNNajibah Nasrin
Najibah Nasrin
SSSharmily Saiyara
Sharmily Saiyara
HSHridoy Saha
Hridoy Saha
DDDebashis Paul Deb
Debashis Paul Deb
JIJohirul Islam
Johirul Islam
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by β-amyloid deposition, tau hyperphosphorylation, mitochondrial dysfunction, oxidative stress, neuroinflammation, and blood–brain barrier disruption, collectively leading to widespread cortical and subcortical atrophy. Current FDA‐approved pharmacotherapies, including acetylcholinesterase inhibitors and memantine, provide only modest symptomatic relief and fail to halt disease progression, underscoring the urgent need for alternative therapeutic approaches. Growing evidence highlights medicinal plants and their bioactive phytoconstituents as promising candidates for AD prevention and treatment because of their multitarget mechanisms, favorable safety profiles, and long history of traditional use. This review synthesizes extensive in vitro, in vivo, and clinical studies demonstrating the neuroprotective potential of plant extracts and isolated compounds that exert antioxidant, anti‐inflammatory, antiamyloidogenic, anti‐tau, cholinesterase‐inhibitory, and synaptic‐modulating effects. Key medicinal species, including Abelmoschus esculentus, Brassica oleracea, Cannabis sativa, Citrus reticulata, Lantana camara, Launaea taraxacifolia, Lawsonia inermis, Marrubium vulgare, Markhamia lutea, Persicaria minor, Pithecellobium dulce, Salvia aristata, Trigonella foenum-graecum , and Withania somnifera, show significant cognitive and neuroprotective benefits in experimental AD models. Phytochemicals such as sulforaphane, nobiletin, trigonelline, diosgenin, verbascoside, withaferin A, and withanolides strongly modulate the amyloid, tau, oxidative, and inflammatory pathways. Clinical trials further support the therapeutic potential of several plant‐derived interventions for mild cognitive impairment and AD‐related dementia. Collectively, these findings highlight medicinal plants and their active constituents as compelling complementary or translational strategies for AD management, warranting further mechanistic and clinical validation. This review aims to evaluate the neuroprotective potential of medicinal plants and their bioactive compounds in preventing and managing AD by summarizing evidence from in vitro, in vivo, and clinical studies.

13 January 2026 in Journal of Infection and Public Health
Verified
Journal Article
Open access
NNNajibah Nasrin
Najibah Nasrin
AMAsfia Hasan Mumu
Asfia Hasan Mumu
APAbir Hasan Pranto
Abir Hasan Pranto
MIMd. Rabiul Islam
Md. Rabiul Islam
The emergence of the JN.1 variant of SARS-CoV-2 has heightened global health concerns. Here, we aimed to evaluate viral characteristics, epidemiology, transmissibility, infectivity, immune evasion, effectiveness of current antiviral therapies, immunization options, genomic surveillance and public awareness against the stealthy JN.1. We searched across key databases to identify recent insights regarding JN.1 variant. This review provides a comprehensive overview of the virological characteristics and public health implications. Early genomic analyses reveal notable mutations in the spike protein, which may enhance viral transmissibility and immune escape. The findings indicate JN.1 to exhibit greater infectivity and enhanced ability to circumvent immune defenses attributable to one mutation identified as L455S. Public health agencies worldwide are enhancing monitoring, genomic surveillance, data sharing, revising containment strategies, promoting booster vaccination campaigns Furthermore, it is imperative to promote public adherence and global collaboration in encouraging the practice of preventive strategies to mitigate potential threat posed by JN.1.

4 November 2025 in Natural Product Communications
Verified
Journal Article
Open access
MAMostari Alija
Mostari Alija
MSMd Abdus Samadd
Md Abdus Samadd
NNNajibah Nasrin
Najibah Nasrin
MHMobarak Hossain
Mobarak Hossain
FNFahim Nakib
Fahim Nakib
AIAshraful Islam
Ashraful Islam
Objective: The investigation aimed to reveal in-vivo therapeutic efficacy of the D. trifoliata 's leaves ethyl acetate extract (EACE) in mice model in addition to the isolation and detection of phyto-molecules. Methods and materials: Phyto-molecules were isolated through chromatographic techniques and detected via nuclear magnetic resonance (NMR) approaches. Tail immersion, and acetic acid-induced writhing method were used for central and peripheral analgesic, respectively, whereas hypoglycemic and CNS depression efficacy were evaluated by oral glucose tolerance test, and thiopental-induced test, respectively. The 200, 400, and 600 mg/kg b.w. doses of EACE were used for all in vivo experiments. Results: Four different compounds (4-hydroxy benzoic acid A , kaempferol B , Baicalein C , stigmasterol D ) were detected via NMR technique, where A and C were firstly isolated molecules from this species. The 600 mg/kg b.w. significantly prolonged reaction times (14.07 ± 0.44 s at 90 min; p < 0.001), confirming strong central analgesic activity. In the peripheral analgesic model, it produced a prominent dose-dependent efficacy with 34.91%, 58.49%, and 65.03% inhibition at 200, 400, and 600 mg/kg, respectively. The EACE also exerted a significant antidiarrheal activity (82.20% inhibition at 600 mg/kg b.w.). In the hypoglycemic assay, the extract elicited mild glucose-lowering effects, the highest reduction observed at 600 mg/kg (4.90 ± 0.42 mmol/L at 90 min). Additionally, CNS depressant activity was at moderate level, as the extract reduced sleep onset (33.75 ± 4.56 min) and extended sleep duration (182.5 ± 10.50 min; p < 0.01) in mice. Conclusion: EACE showed some specific in vivo efficacy in dose dependent manner such as analgesic and diarrhea. Further extensive investigation, is needed to identify the responsible lead compounds.


16 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MAMD. HAFEZ HAFEZ AHMED
MD. HAFEZ HAFEZ AHMED
NNNajibah Nasrin
Najibah Nasrin
MIMd Mehedi Hasan Ifti
Md Mehedi Hasan Ifti
MSMusab Shahariar
Musab Shahariar
LBLamia Hasan Joarder Barsha
Lamia Hasan Joarder Barsha
ASArghya Prosun Sarkar
Arghya Prosun Sarkar
Leea macrophylla is used in traditional medicine in Bangladesh, yet its whole plant has been little examined for analgesic, antidiarrheal and central nervous system (CNS) effects. A methanolic whole-plant extract (MELM) was profiled by gas chromatography–mass spectrometry (GC–MS). Male Swiss albino mice received MELM (200, 400 and 600 mg/kg) in tail-flick, formalin-induced paw-licking and biting, castor oil-induced diarrhea and phenobarbitone-induced sleep tests. Identified compounds were docked to the μ-opioid receptor, cyclooxygenase-2 (COX-2), M3 muscarinic receptor and GABA_A receptor and screened by ADMET (absorption, distribution, metabolism, excretion, toxicity) prediction. GC–MS identified 67 compounds, chiefly fatty acid derivatives and phytol. MELM increased tail-flick latency in a dose- and time-dependent manner and reduced formalin-induced licking and biting by up to 74.19% (600 mg/kg). Fecal output fell by 82.24% at 200 mg/kg, with weaker effects at higher doses. MELM shortened phenobarbitone-induced sleep, significantly at 200 and 400 mg/kg, which does not indicate CNS depression. Campesterol and lanosterol ranked among the top-scoring compounds for several targets and met all ADMET criteria. MELM shows analgesic activity in mice and these sterols warrant further experimental validation.